Company Overview and News

0
Biggest losers: These 10 stocks have lost over 50% in the past 6 months

2018-06-30 moneycontrol
The first half of CY 2018 saw the Sensex hit a peak of 36,443 and many stocks gave high returns. However, the value of these 10 stocks plunged drastically over the past six months. The market cap of these companies is above Rs 1,000 crore. Check out how much percent these stocks have fallen. All figures are year-to-date (YTD) as of June 22, 2018. (Image: Reuters)
HIN 500185 HCC

0
Billionaire’s Folly Becomes Bankers’ Nightmare - Bloomberg

2018-06-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HIN 500185 HCC

3
Bloomberg’s Week in Pictures - Bloomberg

2018-06-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
WFM HIN 500185 WGO HCC

0
Lavasa, a billionaire’s dream project, becomes a nightmare for bankers

2018-06-19 livemint
Mumbai: This onetime hilltop paradise is becoming for some a hell on earth. The days of zero crime are over. Garbage collection is sporadic, so litter soils the man-made lake. Storefronts are vacant. Signs of neglect are everywhere: maintenance is late or non-existent. And that’s for the construction already done. For the unfinished building works—i.e. most of it—there is little happening.
HIN 500185 HCC

0
A billionaire’s folly becomes nightmare for bankers in India

2018-06-19 malaymail
MUMBAI, June 19 — This onetime hilltop paradise is becoming for some a hell on earth.
HIN 500185 HCC

0
Hindustan Construction wins Rs737 crore contract for Bangladesh nuclear power plant

2018-06-06 livemint
New Delhi:Hindustan Construction Co (HCC) on Wednesday announced that its JV with MAX Group has won a Rs737 crore contract from Russia for a nuclear power plant in Bangladesh.
HIN 500185 HCC

11
Sensex ends over 275 points higher, Nifty near 10,700 after RBI hikes repo rate

2018-06-06 moneycontrol
A three-day losing streak broken and how! Equity benchmarks had a good day of trade, with the Sensex closing 275 points higher, while the Nifty closed near 10,700-mark.
500820 TCHQY HIN ASIANPAINT 532755 CADILAHC CDLYY TECHM 532321 HDB 500180 HDFCBANK 500570 500185 TATAMOTORS HCC TTM

0
HCC bags Rs 737 cr contract for Bangladesh nuclear power plant

2018-06-06 moneycontrol
Hindustan Construction Co (HCC) today announced that its JV with MAX Group has won a Rs 737 crore contract from Russia for a nuclear power plant in Bangladesh. The contract includes civil works of Turbine Island for Unit 1 of Rooppur Nuclear Power Plant (NPP).
HIN 500185 HCC

0
HCC surges 7% on contract win by JV in Bangladesh worth Rs 737 cr

2018-06-06 moneycontrol
Share price of Hindustan Construction Company (HCC) surged 7 percent intraday Wednesday as company won a contract worth Rs 737 crore.
HIN 500185 HCC

0
Lavasa struggles to find new directors

2018-06-06 livemint
Bengaluru: Lavasa Corp. Ltd, which is building India’s first mountain city near Pune, has struggled to find directors for the past few years, forcing the debt-laden company to name junior employees, including a receptionist, to its board.
HIN 500185 HCC

1
32 auditors at listed firms have resigned in last 5 months

2018-06-04 livemint
Mumbai: In the past one month, fifteen auditors have resigned prematurely, besides increasing audit qualifications. The total number of exits, so far, in this calendar year stands at a staggering 32.
EDELWEISS BHUSANSTL 532617 JETAIRWAYS HIN 532922 500185 MANPASAND 500055 HCC 539207

0
Delhi HC asks NHAI to pay remaining 25% of multiple arbitral awards to HCC in 2 weeks

2018-05-03 livemint
New Delhi: The Delhi high court on Thursday directed the National Highway Authority of India (NHAI) to pay the remaining 25% of multiple arbitral awards—amounting more than Rs2,000 crore—to Hindustan Construction Co Ltd (HCC) within two weeks.
HIN 500185 HCC

0
HCC posts biggest intraday percentage loss since 2008

2018-05-03 thehindubusinessline
Auditor of the company’s unit Lavasa Corp says it has “significant doubts about the company’s ability to continue as a going concern”
HIN 500185 HCC

3
High-debt cos’ scrips suffer in Q1 of 2018

2018-04-13 thehindubusinessline
The first quarter of calendar year 2018 has not been too good for Indian investors, with benchmark indices reversing sharply in February.
BAJAJHIND BALRAMCHIN 534690 BHUSANSTL HIN 532712 514034 PNJZY RCOM 532461 LAKSHVILAS JBFIND PNB 500038 500185 500032 500055 HCC

0
HCC#39;s Lavasa to file for bankruptcy?

2018-03-22 moneycontrol
Lavasa Corporation, a subsidiary of Hindustan Construction Company (HCC), in a reply to BSE query, has clarified that the media report about the company filing for bankruptcy is 'misleading' and 'without any basis'.
HIN 500185 HCC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

21h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

23h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...